Sentinel Oncology Ltd. could earn up to $174 million from an alliance with Oncothyreon Inc., on its preclinical drug development program targeting checkpoint kinase 1 (Chk1). more »
What with federal Sunshine reporting, state transparency rules and a Medicare data dump, drugmakers are awash in a sea of data that could come back to swamp them. In addition, drugmakers must be on the lookout for whistleblowers. more »
When cancers become resistant to the drugs used to treat them, it has become possible – at least in principle – to understand the cause of that resistance through sequencing, and if a drug exists that is effective against cells with the mutation, to change a patient's treatment accordingly. But a better strategy might be to prevent resistance from developing at all.more »
LONDON – The two molecules, one on the egg and one on the sperm, that interact with each other at the moment of fertilization are now known.
- Glaxosmithkline, Novartis ink 'supercomplex' $26.65B deal in a three-way transaction
- Valeant $45B Allergan bid clever, but will board go along?
- Oncothyreon halts at Sentinel's checkpoint: Deal worth up to $174M
- Principia lands $50M series B to support a leap to the clinic
- FDA finalizes a 15-year-old sameness map for orp...
When cancers become resistant to the drugs used to treat them, it has become possible – at least in principle – to understand the cause of that resistance through sequencing, and if a drug exists that is effective against cells with the mutation, to change a patient's treatment accordingly. But a better strategy might be to prevent resistance from developing at all.
More than 150,000 Americans undergo weight loss surgery annually. But according to a new study, it may be possible to ditch the scalpel but still reap the benefits of the procedure, either through drugs or even, possibly, changes to the diet.READ MORE »
- A prostaglandin synthesis inhibitor that's good for the heart »
- Nanotechnology: Scientific promise meets business perils »
- Bridging big data valley of death that comes before valley of death »
- Gene therapy success in mouse model of neurodegenerative disease »
- Palbociclib shows PFS but not (yet?) OS benefit in phase II »
- Flu vaccine candidate protects against multiple viruses »
- In some cases, more to Alzheimer’s than just amyloids »
- ‘Completely new’ cancer treatment strategy will start clinical trials in 2015 »
- Study reveals complex view of diabetes »
- Hamburg: Society needs to weigh inApril 10, 2014 | 7:10 PM | Posted by: Mari Serebrov
- Bear hunting with biotech’s naysayersApril 08, 2014 | 7:37 PM | Posted by: Peter Winter
- Rock to the left, hard place to the right: One dilemma of compassionate useMarch 13, 2014 | 4:16 PM | Posted by: Jennifer Boggs
- Human germline engineering: The mom’s not in the pictureMarch 04, 2014 | 3:17 PM | Posted by: Anette Breindl
- Biosimilar regulation: 1984 v. 2014February 19, 2014 | 9:06 PM | Posted by: Mari Serebrov
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter